Efficacy of mesenchymal stem cell therapy for treating deep corneal ulcers and corneal perforation in cats: a retrospective study
Sritrakoon N., Thayananuphat A., Teekasang T., Nimsuphan B.
Animal Study, published in J Feline Med Surg (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- J Feline Med Surg (2026)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41622128
- PMCID
- PMC12961127
- DOI
- 10.1177/1098612x261423236
Abstract (original English)
ObjectivesThis study evaluated the therapeutic effects of subconjunctival injection of mesenchymal stem cells (MSCs) for treating deep corneal ulcers and corneal perforation in cats.MethodsOf the 24 cats identified with a deep corneal ulcer or perforation, 17 received MSCs and medical treatment; among them, six had deep corneal ulcers and 11 had corneal perforations. Of the seven cats that received only medical treatment, three cats had deep corneal ulcers and four cats had corneal perforations. All were monitored with fluorescein staining at 3-4 days and weekly assessments after MSC injection until fluorescein-negative status was achieved.ResultsOutcomes were compared between cats treated with subconjunctival MSC injections and MSC-untreated cats. Based on the results, 15/17 (88%) cats treated with MSCs became fluorescein-negative within 1-3 weeks, whereas 2/17 (12%) of those receiving subconjunctival MSC injections achieved this outcome within 5-6 weeks. During the mean follow-up period of 146 ± 138 days (range 15-398) after MSC injection, recurrence of corneal perforations was observed in four cats that were ultimately completely healed. All deep corneal ulcers healed uneventfully. In the MSC-untreated group, 4/7 (57%) achieved fluorescein-negative status within 3-7 weeks, while another 2/7 (29%) experienced recurrent corneal perforation on days 3 and 58, requiring conjuncti
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.